The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial.
 
Abiola Oladapo
Employment - SOBI
Stock and Other Ownership Interests - Biogen (I); Takeda
Research Funding - Alexion Pharmaceuticals (I); SOBI
Travel, Accommodations, Expenses - Alexion Pharmaceuticals (I); SOBI
 
Karisse Roman-Torres
Employment - SOBI
Research Funding - SOBI
Travel, Accommodations, Expenses - SOBI
 
Aaron Gerds
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; CTI; GlaxoSmithKline/Sierra Oncology; Imago Pharma; Kartos Therapeutics; MorphoSys; Pharmaessentia; Rain Therapeutics
Research Funding - Celgene; CTI; Gilead Sciences; Incyte; Pfizer; Roche/Genentech
 
Stephen Oh
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Cogent Biosciences; Constellation Pharmaceuticals; CTI BioPharma Corp; Geron; Incyte; Protagonist Therapeutics; Sierra Oncology
Research Funding - Actuate Therapeutics; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Cogent Biosciences; Constellation Pharmaceuticals; CTI BioPharma Corp; Incyte; Ionis Pharmaceuticals; Kartos Therapeutics; PharmaEssentia; Sierra Oncology; Takeda